Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$66.43 USD

66.43
6,113,788

-2.50 (-3.63%)

Updated Sep 5, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Align Unveils Vivera Retainers for Deep Bite Correction

Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.

    Walgreens Boots' Retail Business Solid Amid Several Concerns

    Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.

      Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance

      Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.

        Walgreens Boots (WBA) Beats on Earnings in Q2, Lifts View

        Walgreens Boots (WBA) witnesses revenue growth across all three segments in Q2. A solid guidance instills investor confidence in the stock.

          DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System

          DexCom (DXCM) is a leading player in the global CGM markets.

            Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?

            Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.

              3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax

              Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.

                Can Edwards Lifesciences (EW) Stock Continue to Grow Earnings?

                Edwards Lifesciences (EW) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.

                  Medical Device Industry Outlook - February 2018

                  Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.

                    Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

                    Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

                      Here's Why You Should Invest in Edwards Lifesciences (EW) Now

                      Recent buyouts and CE Mark boost investors' confidence in Edwards Lifesciences (EW).

                        Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm

                        Edward Lifesciences (EW) witnesses multiple developments in THV segment.

                          Ryan McQueeney headshot

                          Markets Are Down, But These Stocks Surged to All-Time Highs Today

                          Friday has been a rough day on Wall Street, with several major indexes--including the Dow, Nasdaq, and S&P 500--hovering deep in the red during early afternoon trading hours. Nevertheless, several notable stocks touched new all-time highs during the day. Check them out!

                            Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?

                            Edwards Lifesciences (EW) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                              Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

                              Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

                                Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio

                                Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.

                                  Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

                                  Edwards Lifesciences (EW) needs investors to pay close attention to the stock based on moves in the options market lately.

                                    EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

                                    Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

                                      Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?

                                      Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.

                                        Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day

                                        Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day

                                          Align Technology (ALGN) Prospects Bright, Competition Rife

                                          Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                                            Kevin Cook headshot

                                            Bull of the Day: Edwards Lifesciences (EW)

                                            The #1 non-surgical heart valve replacement technology owes its roots to a hydraulic pump engineer named Miles Edwards

                                              Medtronic Advances in Pain Therapy With U.S. Intellis Launch

                                              We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.

                                                Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                                The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

                                                  Amedisys or Chemed: Which is a Better Investment Choice?

                                                  After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).